Fifty1 Labs, Inc. Subsidiary Fifty1 AI Labs Partners with ViRx@Stanford Under 'BE READI!' Initiative to Advance AI-Powered Antiviral Drug Repurposing
Fifty1 Labs (OTC: FITY) announced a strategic partnership between its subsidiary Fifty1 AI Labs and ViRx@Stanford under the 'BE READI!' initiative. The collaboration aims to leverage Fifty1's AI platform for antiviral drug repurposing to combat potential pandemic threats.
The partnership will benefit from ViRx's connection to Stanford's SyneRx antiviral hub, which received a $69 million NIAID grant. The initiative focuses on developing outpatient antiviral cocktails against SARS-CoV-2 and other RNA viruses, combining Fifty1's AI capabilities with ViRx's global research network spanning Vietnam, Israel, Brazil, and Mongolia.
Fifty1 Labs (OTC: FITY) ha annunciato una partnership strategica tra la sua controllata Fifty1 AI Labs e ViRx@Stanford nell'ambito dell'iniziativa «BE READI!». La collaborazione sfrutterà la piattaforma di intelligenza artificiale di Fifty1 per il riposizionamento di farmaci antivirali con l'obiettivo di contrastare potenziali minacce pandemiche.
La partnership beneficerà della connessione di ViRx con lo hub antivirale SyneRx di Stanford, che ha ottenuto un finanziamento NIAID di 69 milioni di dollari. L'iniziativa mira a sviluppare cocktail antivirali per pazienti ambulatoriali contro SARS-CoV-2 e altri virus a RNA, integrando le capacità AI di Fifty1 con la rete di ricerca globale di ViRx in Vietnam, Israele, Brasile e Mongolia.
Fifty1 Labs (OTC: FITY) anunció una alianza estratégica entre su filial Fifty1 AI Labs y ViRx@Stanford dentro de la iniciativa «BE READI!». La colaboración aprovechará la plataforma de IA de Fifty1 para el reposicionamiento de fármacos antivirales con el fin de enfrentar posibles amenazas pandémicas.
La asociación se beneficiará de la vinculación de ViRx con el centro antivírico SyneRx de Stanford, que recibió una subvención NIAID de 69 millones de dólares. La iniciativa se centra en desarrollar cócteles antivirales para pacientes ambulatorios contra el SARS-CoV-2 y otros virus de ARN, combinando las capacidades de IA de Fifty1 con la red de investigación global de ViRx en Vietnam, Israel, Brasil y Mongolia.
Fifty1 Labs (OTC: FITY)는 자회사 Fifty1 AI Labs와 ViRx@Stanford가 'BE READI!' 이니셔티브 하에 전략적 파트너십을 맺었다고 발표했습니다. 이번 협력은 잠재적 팬데믹 위협에 대응하기 위해 Fifty1의 AI 플랫폼을 활용한 항바이러스제 재배치(약물 재활용)를 목표로 합니다.
이 파트너십은 스탠퍼드의 항바이러스 허브 SyneRx와 연계된 ViRx의 네트워크를 통해 혜택을 받게 되며, 해당 허브는 6900만 달러 규모의 NIAID 보조금을 받았습니다. 이 이니셔티브는 SARS-CoV-2 및 기타 RNA 바이러스에 대한 외래 환자용 항바이러스 혼합요법 개발에 주력하며 Fifty1의 AI 역량과 베트남, 이스라엘, 브라질, 몽골에 걸친 ViRx의 글로벌 연구 네트워크를 결합합니다.
Fifty1 Labs (OTC: FITY) a annoncé un partenariat stratégique entre sa filiale Fifty1 AI Labs et ViRx@Stanford dans le cadre de l'initiative « BE READI! ». La collaboration vise à exploiter la plateforme d'IA de Fifty1 pour le repositionnement de médicaments antiviraux afin de lutter contre d'éventuelles menaces pandémiques.
Le partenariat tirera parti du lien de ViRx avec le pôle antiviral SyneRx de Stanford, qui a reçu une subvention NIAID de 69 millions de dollars. L'initiative se concentre sur le développement de cocktails antiviraux en ambulatoire contre le SARS-CoV-2 et autres virus à ARN, en combinant les capacités d'IA de Fifty1 avec le réseau mondial de recherche de ViRx au Vietnam, en Israël, au Brésil et en Mongolie.
Fifty1 Labs (OTC: FITY) gab eine strategische Partnerschaft zwischen seiner Tochtergesellschaft Fifty1 AI Labs und ViRx@Stanford im Rahmen der Initiative ‚BE READI!‘ bekannt. Die Zusammenarbeit zielt darauf ab, Fifty1s KI-Plattform für das Repositioning antiviraler Medikamente zu nutzen, um potenziellen Pandemierisiken zu begegnen.
Die Partnerschaft profitiert von ViRx' Verbindung zum antiviralen Zentrum SyneRx der Stanford University, das eine 69-Millionen-Dollar-NIAID-Förderung erhalten hat. Die Initiative konzentriert sich auf die Entwicklung ambulanter antiviraler Cocktailtherapien gegen SARS-CoV-2 und andere RNA-Viren und kombiniert Fifty1s KI-Fähigkeiten mit ViRx' weltweitem Forschungsnetzwerk in Vietnam, Israel, Brasilien und der Mongolei.
- Partnership with prestigious Stanford University's ViRx initiative enhances credibility and research capabilities
- Access to significant resources through SyneRx's $69 million NIAID grant
- Global reach through international research hubs in multiple countries
- AI-driven approach could accelerate drug development and reduce costs
- Early-stage collaboration with no immediate revenue impact
- Operating in highly competitive antiviral drug development space
- Success depends on unproven AI platform effectiveness
Collaboration Aims to Accelerate Therapies for Proactive Pandemic Defense
STANFORD, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- via IBN – ViRx@Stanford, a leading biosecurity and pandemic preparedness initiative, and Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), an innovative AI-driven drug repurposing company, today announced a strategic partnership under the "BE READI!" initiative. This collaboration will leverage Fifty1's advanced AI platform to repurpose existing drugs into potent antiviral therapies, addressing urgent viral threats and enhancing global health security.
The partnership positions the collaboration within ViRx's "BE READI!" (Biosecurity & Pandemic Preparedness Initiative), emphasizing proactive measures to safeguard global health against emerging pandemics. By harnessing Fifty1's AI capabilities, the initiative will accelerate drug repurposing, enabling rapid development of antiviral treatments that can be deployed swiftly—critical in scenarios where vaccine rollout may take up to a year.
This alliance launches a series of exploratory AI-driven projects designed to expand the antiviral toolkit. Drawing lessons from the devastating impacts of past pandemics, including approximately 10 million deaths from COVID-19 and 50-100 million from the 1918 influenza, the partnership pivots toward future readiness, aiming to mitigate similar or greater mortality in potential outbreaks.
"ViRx's mission to equip the world with early antiviral defenses perfectly complements Fifty1's AI-accelerated, 'safe by design' drug repurposing platform," said Paul Arora, CEO of Fifty1 Labs, Inc. "Together, we're not just responding to threats—we're staying ahead of them, combining scientific rigor with innovative speed to protect lives."
Backed by Stanford's world-class SyneRx antiviral hub, which received a US
"This partnership exemplifies how AI can revolutionize antiviral drug discovery, from target identification to clinical prediction," said ViRx Senior Scientist Ed Mills, "By mobilizing Fifty1's platform alongside our global resources, we're building a scalable model that starts at Stanford and extends to international hubs, ensuring rapid, equitable access to life-saving therapeutics."
Together, ViRx and Fifty1 are forging a global, scalable framework for pandemic response. From Stanford's innovation ecosystem to worldwide collaborations—including deputy directors in Vietnam, Israel, Brazil, and Mongolia—the initiative integrates AI and repurposed therapeutics to protect future generations, resonating with stakeholders seeking high-impact, sustainable solutions.
About ViRx@Stanford
ViRx@Stanford is a Stanford-based initiative focused on advancing antiviral drug development to enhance biosecurity and pandemic preparedness. Spinning out of groundbreaking Stanford research, it harnesses cutting-edge AI to accelerate pharmaceutical innovation, aiming to expand the collective antiviral toolkit proactively. With a global network of deputy directors and partnerships, ViRx@Stanford seeks to protect future generations from pandemics by developing life-saving therapies faster and more cost-effectively, starting locally and building out to combat viral diseases worldwide. Visit https://virx.stanford.edu for more information.
About Fifty1 AI Labs
Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), is redefining drug discovery by using AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.
Contact:
Investor Relations
Fifty 1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1AIlabs.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the potential impact, development, and timeline of AI-powered drug repurposing for antiviral therapies, the launch of exploratory AI-driven projects for pandemic readiness, and the ability of Fifty1 AI Labs' platform to transform antiviral treatment strategies and global health security, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the success and timing of partnerships and projects, the efficacy and safety of repurposed treatments, regulatory approvals, and the company's ability to successfully develop and commercialize its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, please refer to Fifty1 Labs, Inc.'s filings with the OTC Markets. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the purpose of Fifty1 Labs' partnership with ViRx@Stanford?
How much funding does the Stanford SyneRx antiviral hub have from NIAID?
Which countries are involved in the Fifty1 Labs and ViRx@Stanford collaboration?
What is the main technology Fifty1 Labs (FITY) brings to the partnership?
What types of viruses will the Fifty1 Labs-ViRx partnership focus on?
